EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 166 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,098 | +3.3% | 106 | 0.0% | 0.00% | – |
| Q3 2022 | $3,000 | -40.0% | 106 | 0.0% | 0.00% | – |
| Q2 2022 | $5,000 | +150.0% | 106 | +130.4% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 46 | -6.1% | 0.00% | – |
| Q4 2021 | $2,000 | -33.3% | 49 | +2.1% | 0.00% | – |
| Q3 2021 | $3,000 | +50.0% | 48 | 0.0% | 0.00% | – |
| Q2 2021 | $2,000 | +100.0% | 48 | +54.8% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 31 | +19.2% | 0.00% | – |
| Q4 2020 | $1,000 | -50.0% | 26 | -43.5% | 0.00% | – |
| Q3 2020 | $2,000 | -50.0% | 46 | -47.7% | 0.00% | – |
| Q2 2020 | $4,000 | 0.0% | 88 | -2.2% | 0.00% | – |
| Q1 2020 | $4,000 | -33.3% | 90 | -5.3% | 0.00% | – |
| Q4 2019 | $6,000 | +20.0% | 95 | +5.6% | 0.00% | – |
| Q3 2019 | $5,000 | – | 90 | +4400.0% | 0.00% | – |
| Q4 2017 | $0 | -100.0% | 2 | -96.3% | 0.00% | – |
| Q3 2017 | $3,000 | +50.0% | 54 | +170.0% | 0.00% | – |
| Q2 2017 | $2,000 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 112,666 | $1,777 | 0.65% |
| Smith, Graham & Co., Investment Advisors, LP | 273,099 | $4,306,771 | 0.54% |
| BRANDES INVESTMENT PARTNERS, LP | 1,134,363 | $17,888,904 | 0.35% |
| TANG CAPITAL MANAGEMENT LLC | 118,857 | $1,874,375 | 0.26% |
| Virtus Investment Advisers, Inc. | 20,867 | $329,073 | 0.22% |
| DENALI ADVISORS LLC | 32,300 | $509,371 | 0.18% |
| Nebula Research & Development LLC | 11,473 | $180,929 | 0.10% |
| SCOUT INVESTMENTS, INC. | 131,192 | $1,995,430 | 0.05% |
| XTX Topco Ltd | 15,050 | $237,339 | 0.04% |
| PDT Partners, LLC | 19,745 | $311,379 | 0.04% |